DepoMed Inc. (DEPO) shares are up $0.65 to $21.15 in after-hours trading Monday after the company reported its fourth quarter earnings results.
The Newark, Calif.-based pharmaceutical firm reported non-GAAP earnings of $0.21 per share on revenues of $194.6 million, up 379.20% from a year ago. Analysts were expecting EPS of $0.07 on revenues of $43.24 million.
For full year 2014, revenues came in at 390.4 million. On a GAAP basis, full year EPS was $2.05 vs. a non-GAAP of $0.26.
On valuation measures, DepoMed Inc. shares, which currently have an average 3-month trading volume of 923,774 shares, trade at a trailing-12 P/E of 15.73, a forward P/E of 52.56 and a P/E to growth ratio of 6.57. The median Wall Street price target on the name is $24.00 with a high target of $26.00. Currently ticker boasts 3 ‘Buy’ endorsements, compared to 0 ’Holds’ and no ‘Sell’.
Profitability-wise, DEPO has a t-12 profit and operating margin of 33.40% and 38.11%, respectively. The $1.20 billion market cap company reported $566.40 million in cash vs. $226.77 million in debt in its most recent quarter.
DEPO currently prints a one year return of about 56% ,and a year-to-date return of around 25%.
The chart below shows where the equity has traded over the last 52 weeks.
DepoMed Inc. is a specialty pharmaceutical company focused on pain and neurology. The firm was founded in 1995 and is headquartered in Newark, California.